USPTO serial 87322935
IMMULYTIC
Reviewed by CopyMark Law Group
Reg. 5353767Status 710
- Filing date
- Status date
- Registration date
- Dec 12, 2017
- Examiner
- JOHNSON, CLINTON J
- Law office
- POST REGISTRATION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with IMMULYTIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Oxfordshire, GB
Oxfordshire, GB
Oxfordshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Melanie Howard, Esq.
MELANIE HOWARD, ESQ. LOEB & LOEB LLP10100 SANTA MONICA BLVD STE 2200LOS ANGELES, CA 90067-4120UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; viruses for the treatment of cancer and tumors; viruses for inducing immune response for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceutical preparations and pharmaceutical substances for the treatment of infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceutical preparations and pharmaceutical substances used for the prevention and treatment of cancer and tumors; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response for the treatment of cancer and tumors; vaccines; immunotherapy products, namely, pharmaceuticals for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 28, 2024 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Dec 12, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 14, 2019 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Feb 14, 2019 | PLGL | ASSIGNED TO PARALEGAL | — |
| Feb 13, 2019 | PINT | REPRINTING REGISTRATION CERTIFICATE | — |
| Sep 20, 2018 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Sep 10, 2018 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Apr 6, 2018 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Mar 28, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 20, 2018 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Dec 12, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 26, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 26, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 6, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 19, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 18, 2017 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Aug 14, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 14, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 14, 2017 | ALIE | ASSIGNED TO LIE | — |
| Aug 4, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 4, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 19, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 11, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 4, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 7, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 6, 2017 | NWAP | NEW APPLICATION ENTERED | — |